Back to Directory
N2 Pharmaceuticals
Scotland
Founded 2013
Blue-mussel-derived bioactive peptide therapy for veterinary research
N2 Pharmaceuticals develops N2-01, an injectable mixture of bioactive peptides and amino acids derived from blue mussels.
Its research focuses on endothelial dysfunction and vascular permeability, with potential applications in veterinary medicine and human disease. The company reports historic veterinary use in Russia and preclinical laboratory research; UK or EU marketing authorisation has not been established.
Founded in 2013, N2 Pharmaceuticals maintains an association with Roslin Innovation Centre.
Company Notes
Previously Known As
Marimix
Member of